SVB Leerink Weighs in on Jazz Pharmaceuticals plc’s Q4 2022 Earnings (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) – Research analysts at SVB Leerink cut their Q4 2022 earnings estimates for Jazz Pharmaceuticals in a research report issued to clients and investors on Thursday, April 21st. SVB Leerink analyst M. Goodman now anticipates that the specialty pharmaceutical company will earn $2.85 per share for the quarter, down from their previous estimate of $3.41.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last posted its quarterly earnings results on Tuesday, March 1st. The specialty pharmaceutical company reported $3.66 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.68. The company had revenue of $896.73 million during the quarter, compared to the consensus estimate of $866.71 million. Jazz Pharmaceuticals had a positive return on equity of 21.56% and a negative net margin of 10.65%. The firm’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.56 EPS.

Other research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 2nd. Truist Financial lifted their target price on Jazz Pharmaceuticals from $180.00 to $200.00 in a report on Thursday, January 20th. Needham & Company LLC reissued a “buy” rating and issued a $215.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, February 7th. Piper Sandler cut their price objective on shares of Jazz Pharmaceuticals from $209.00 to $197.00 and set an “overweight” rating for the company in a research report on Wednesday, March 2nd. Finally, HC Wainwright upped their target price on shares of Jazz Pharmaceuticals from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, March 3rd. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $203.92.

JAZZ stock opened at $163.00 on Monday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.90 and a current ratio of 3.23. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of -29.91, a PEG ratio of 1.43 and a beta of 0.87. Jazz Pharmaceuticals has a fifty-two week low of $117.64 and a fifty-two week high of $189.00. The stock has a fifty day moving average of $154.91 and a 200-day moving average of $141.33.

Institutional investors have recently made changes to their positions in the company. BOKF NA purchased a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $1,021,000. Mitsubishi UFJ Trust & Banking Corp boosted its stake in shares of Jazz Pharmaceuticals by 4.9% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 82,028 shares of the specialty pharmaceutical company’s stock valued at $10,680,000 after purchasing an additional 3,848 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Jazz Pharmaceuticals by 807.5% in the 3rd quarter. Assetmark Inc. now owns 83,139 shares of the specialty pharmaceutical company’s stock valued at $10,826,000 after purchasing an additional 73,978 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of Jazz Pharmaceuticals by 82.8% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 29,417 shares of the specialty pharmaceutical company’s stock valued at $3,830,000 after purchasing an additional 13,324 shares in the last quarter. Finally, Royal London Asset Management Ltd. boosted its position in Jazz Pharmaceuticals by 11.6% during the 4th quarter. Royal London Asset Management Ltd. now owns 20,235 shares of the specialty pharmaceutical company’s stock valued at $2,579,000 after buying an additional 2,099 shares during the period. 91.95% of the stock is owned by institutional investors.

In related news, CEO Bruce C. Cozadd sold 10,772 shares of the firm’s stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $158.33, for a total transaction of $1,705,530.76. Following the transaction, the chief executive officer now directly owns 346,062 shares of the company’s stock, valued at approximately $54,791,996.46. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 6,372 shares of the company’s stock in a transaction that occurred on Tuesday, February 1st. The stock was sold at an average price of $139.23, for a total value of $887,173.56. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

See Also

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.